Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial (Q28294837)

1

0 references

Alexander J. Foss

1 reference

ORCID Public Data File 2021

author name string

Chris A Rogers

3

0 references

Susan M Downes

4

0 references

Andrew J Lotery

5

0 references

Lucy A Culliford

6

0 references

Barnaby C Reeves

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study

7

0 references

language of work or name

English

0 references

publication date

12 October 2013

0 references

published in

The Lancet

0 references

volume

382

0 references

page(s)

1258-67

0 references

issue

9900

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961501-9

7 January 2021

Ranibizumab for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961501-9

7 January 2021

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961501-9

7 January 2021

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961501-9

7 January 2021

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961501-9

7 January 2021

Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961501-9

7 January 2021

Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961501-9

7 January 2021

Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961501-9

7 January 2021

Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961501-9

7 January 2021

Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961501-9

7 January 2021

Bevacizumab for neovascular ocular diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961501-9

7 January 2021

Macular degeneration: do conventional measurements of impaired visual function equate with visual disability?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961501-9

7 January 2021

EuroQol--a new facility for the measurement of health-related quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961501-9

7 January 2021

The MacDQoL individualized measure of the impact of macular degeneration on quality of life: reliability and responsiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961501-9

7 January 2021

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961501-9

7 January 2021

Treatments for macular degeneration: summarising evidence using network meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961501-9

7 January 2021

A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961501-9

7 January 2021

Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961501-9

7 January 2021

A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961501-9

7 January 2021

Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961501-9

7 January 2021

The safety of niacin in the US Food and Drug Administration adverse event reporting database

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961501-9

7 January 2021

Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961501-9

7 January 2021

Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961501-9

7 January 2021

Myocardial infarction after intravitreal vascular endothelial growth factor inhibitors: a whole population study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961501-9

7 January 2021

Risks of adverse events with therapies for age-related macular degeneration: a response.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961501-9

7 January 2021

Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2961501-9

7 January 2021